title: Benefits of low dose immunoglobulin in the treatment of refractory CAPD peritonitis and longevity of technical survival on CAPD.
abstract: In this study we investigated the long term results of intraperitoneal immunoglobulin (Ig) treatment in continuous ambulatory peritoneal dialyses (CAPD) patients with refractory or relapsing peritonitis. Sixteen CAPD patients (4 female, 12 male) with a mean age of 53 +/- 11 years (40-80), with a mean CAPD duration of 46.2 +/- 4.8 months (17-75) were included in the study. The patients included had a diagnosis of either refractory or relapsing peritonitis unresponsive to appropriate antibiotic therapy. 0.5 g of Ig was added to every exchange bag qid as an adjunctive therapy to the culture based antibiotherapy for 7 days. Intraperitoneal Ig treatment was found to be successful in treating peritonitis in all but one patient. Interestingly, following Ig treatment, long term peritonitis rate decreased significantly compared to the period before treatment (before: 2.2 +/- 0.6 episodes/patient/year vs. after: 0.6 +/- 0.17 episodes/patient/year; P = 0.019). The mean CAPD duration after Ig treatment was 30.5 +/- 5.4 (4-64) months. Out of 16 patients, one patient who was unresponsive, had his catheter removed and was switched to hemodialysis, and four patients with preexisting ultrafiltration failure or inadequate dialysis problems were transferred to hemodialysis after successful treatment of their peritonitis, one patient was transplanted and 10 patients continued on CAPD. We conclude that low dose Ig treatment may be beneficial in the treatment of refractory or relapsing CAPD peritonitis possibly through restoring impaired host defense within peritoneal cavity. This therapy, by preventing further peritonitis attacks, may prolong survival on CAPD.
authors.affiliation: Division of Nephrology, Medical School, Pamukkale University, Doktorlar Caddesi, Denizli 20200, Turkey. belda1@yahoo.com
authors.forename: Belda
authors.initials: B
authors.lastname: Dursun
authors.forename: Murat
authors.initials: M
authors.lastname: Tuncer
authors.forename: Rasih
authors.initials: R
authors.lastname: Felek
authors.forename: F Fevzi
authors.initials: FF
authors.lastname: Ersoy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D006435:Renal Dialysis; D012189:Retrospective Studies
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; C495669:Octagam